labetalol has been researched along with Liver Diseases in 6 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus the bioavailability of labetalol was increased in liver disease due to reduced first-pass metabolism." | 2.64 | Decreased first-pass metabolism of labetalol in chronic liver disease. ( Homeida, M; Jackson, L; Roberts, CJ, 1978) |
| " It was a prerequisite to establish the bioavailability of oxazepam prior to succeeding studies on the oral disposition of the drug." | 2.38 | Factors and conditions affecting the glucuronidation of oxazepam. ( Sonne, J, 1993) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Tin, LN | 1 |
| Mulard, C | 1 |
| Talon, A | 1 |
| Garnier, JM | 1 |
| Lambert, A | 1 |
| Stroch-Marcy, A | 1 |
| Kamara, S | 1 |
| Sonne, J | 1 |
| Homeida, M | 1 |
| Jackson, L | 1 |
| Roberts, CJ | 1 |
| Clark, JA | 1 |
| Zimmerman, HJ | 1 |
| Tanner, LA | 1 |
| Douglas, DD | 1 |
| Yang, RD | 1 |
| Jensen, P | 1 |
| Thiele, DL | 1 |
1 review available for labetalol and Liver Diseases
| Article | Year |
|---|---|
Factors and conditions affecting the glucuronidation of oxazepam.
Topics: Acetaminophen; Age Factors; Aged; Aged, 80 and over; Biological Availability; Biotransformation; Die | 1993 |
1 trial available for labetalol and Liver Diseases
| Article | Year |
|---|---|
Decreased first-pass metabolism of labetalol in chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Chronic Disease; Ethanolamines; Female; | 1978 |
4 other studies available for labetalol and Liver Diseases
| Article | Year |
|---|---|
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
[Subcapsular liver hematoma, a HELLP syndrome complication].
Topics: Adult; Cesarean Section; Combined Modality Therapy; Female; HELLP Syndrome; Hematoma; Humans; Labeta | 1994 |
Labetalol hepatotoxicity.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Hepatitis, Vir | 1990 |
Fatal labetalol-induced hepatic injury.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Labetalol; Liver Diseases; Mid | 1989 |